The FDA clears first new sunscreen active ingredient in decades—here’s what physicians should know
Industry Buzz
Europe and Asia have had access to more advanced filters for years, which has allowed lighter textures, better UVA coverage, and fewer issues like chalkiness or heavy feel. Adding bemotrizinol would make US sunscreens more globally competitive.
—Elizabeth Houshmand, MD
For the first time since the late 1990s, the US sunscreen aisle is getting a new active ingredient. On June 9, the FDA added bemotrizinol to the list of permitted active ingredients in over-the-counter sunscreen, clearing the way for products using the UV filter to enter the US market under the OTC sunscreen monograph. []
The move matters for patients, but it may matter just as much for clinicians who find themselves increasingly doing double duty: Recommending photoprotection while also countering social media claims that sunscreen is unnecessary, toxic, or even a “scam.”
The new ingredient is not experimental. Bemotrizinol has been used for years in Europe and other countries, where sunscreen filters have generally evolved faster than in the US. What is new is its regulatory status here. []
“Europe and Asia have had access to more advanced filters for years, which has allowed lighter textures, better UVA coverage, and fewer issues like chalkiness or heavy feel. Adding bemotrizinol makes US sunscreens more globally competitive,” dermatologist Elizabeth Houshmand, MD, told New Beauty. []
More about bemotrizinol
The FDA now considers bemotrizinol generally recognized as safe and effective for use in sunscreens for adults and children 6 months of age and older, at concentrations up to 6%. []
Clinically, the important point is that bemotrizinol offers broad-spectrum coverage, meaning it is active against both UVA and UVB radiation. [] That distinction is worth spelling out for patients.
UVB is the wavelength range most associated with sunburn. UVA penetrates deeper into the skin and contributes to skin damage, skin aging, and wrinkles. []
Patients often think SPF 50 is the whole story, but it’s not. The label phrase “broad-spectrum” is doing a lot of clinical work.
Bemotrizinol is also notable for its reported low systemic absorption. [] That may help physicians answer a common question in the clinic: “Should I be worried that sunscreen chemicals get into my blood?”
The honest answer is nuanced. The FDA has acknowledged that some sunscreen active ingredients can be absorbed through the skin, and it has requested more data on several ingredients historically used in US products. []
Absorption, however, is not the same as harm. The practical counseling point is that the known risks of ultraviolet exposure are clear, while the claim that sunscreen causes skin cancer is not supported by evidence.
That counseling burden has grown heavier. Dermatologists and primary care clinicians are increasingly encountering patients who have heard that sunscreen interferes with “natural sun,” blocks vitamin D, contains dangerous chemicals, or is a marketing ploy.
Some of these claims are old, but the delivery system is new. A short video can make a false claim feel more intuitive than a prevention guideline.
Related: According to social media influencers, sunscreen is a scamThe FDA action gives clinicians a timely opening to reframe the conversation around sunscreen science. Sunscreen is not one product category with one risk-benefit profile. It is a delivery system for UV filters, and those filters differ by spectrum, photostability, cosmetic feel, absorption profile, and compatibility with different vehicles.
Zinc oxide and titanium dioxide remain familiar mineral options. Organic filters such as avobenzone, octocrylene, octisalate, and others are common in US products. [] Bemotrizinol adds another filter option, and likely another formulation tool for manufacturers trying to improve UVA/UVB coverage without sacrificing wearability.
That last point is not cosmetic trivia. Adherence is the clinical endpoint that often gets lost. A sunscreen that pills under makeup, leaves a white cast on darker skin, burns around the eyes, feels greasy, or is hard to reapply is a sunscreen patients may buy once and abandon.
For many patients, the best sunscreen is not the one with the most elegant label claim; it is the one they will apply in adequate amounts, reapply, and use alongside shade, clothing, hats, and sunglasses.
Physicians can also use the bemotrizinol news to reinforce what has not changed: Sunscreen is still one component of photoprotection, not a permission slip for unlimited midday exposure. Patients should look for broad-spectrum protection, use adequate quantities, reapply every 2 hours when outdoors, and reapply sooner after swimming or sweating. []
They should not assume that water-resistant means waterproof. They should not use expired products or bottles that have been baked in a car or beach bag for months. Infants younger than 6 months should generally be kept out of direct sun, with protective clothing and shade favored over routine sunscreen use unless a clinician advises otherwise.
The age point is especially useful for pediatric counseling. The FDA’s bemotrizinol determination applies to adults and children 6 months and older.
That aligns with the broader practical message many pediatricians and dermatologists already give: For babies under 6 months, minimize exposure first; for older infants and children, use sunscreen as directed, along with physical protection.
The regulatory change also highlights a longstanding gap between the US and international sunscreen markets. In the US, sunscreens are regulated as OTC drugs, meaning active ingredients must meet monograph standards for safety and effectiveness.
In some other countries, sunscreens may be regulated differently, including as cosmetics. That distinction helps explain why patients may see different filters in imported products or online recommendations.
For now, the addition of bemotrizinol does not mean patients will see new products immediately. The FDA has cleared the active ingredient under the monograph, but manufacturers determine when products appear on shelves. When they do, doctors may start seeing bemotrizinol listed among active ingredients, potentially under brand-specific or chemical names, depending on labeling.
How to counsel patients who are confused about sunscreen
Start with the risk. UV radiation is a proven driver of sunburn, photoaging, pigmentary change, and skin cancer. Sunscreen helps reduce that risk when used correctly, especially as part of a broader sun-protection plan.
Explain the label in layman’s terms. SPF mainly reflects protection against UVB-related sunburn. “Broad-spectrum” means the product also protects against UVA. For most patients, recommend broad-spectrum SPF 30 or higher, especially for routine outdoor exposure.
Make the choice practical. Mineral sunscreens use zinc oxide and/or titanium dioxide. Chemical or organic sunscreens use UV filters that absorb UV radiation. Both categories can be appropriate. The best option is usually the one the patient will use enough of and reapply.
Explain what’s new. Bemotrizinol is a newly permitted US sunscreen active ingredient, though it has been used in other countries for years. It protects against both UVA and UVB rays and has low skin-to-body absorption. Products may not appear immediately; manufacturers control timing.
Correct the influencer claim directly. If a patient says, “I heard sunscreen is a scam,” avoid dismissing them. Try, “I understand why the posts sound convincing, but UV radiation is the carcinogen here. Sunscreen does not replace shade or clothing, but it is one evidence-based tool that lowers UV damage when used correctly.”
Give the usage script. Apply before sun exposure. Use enough to cover exposed skin. Reapply every 2 hours outdoors, and sooner after swimming or sweating. Cover the ears, scalp, lips, neck, hands, and tops of feet. Don’t rely on sunscreen alone during peak sun hours.
Related: Is 'body wash sunscreen' the next big anti-aging product?